Two Sigma Advisers LP Acquires 33,300 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Two Sigma Advisers LP lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4,757.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,000 shares of the company's stock after acquiring an additional 33,300 shares during the quarter. Two Sigma Advisers LP's holdings in IDEXX Laboratories were worth $17,177,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its position in IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after buying an additional 96 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after purchasing an additional 1,453 shares during the period. National Pension Service increased its position in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after purchasing an additional 12,647 shares in the last quarter. EFG Asset Management Americas Corp. boosted its holdings in IDEXX Laboratories by 45.3% in the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after purchasing an additional 3,966 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $14.99 during mid-day trading on Monday, reaching $450.68. 783,785 shares of the company's stock were exchanged, compared to its average volume of 512,364. The company has a 50-day simple moving average of $444.47 and a two-hundred day simple moving average of $473.85. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The company has a market cap of $36.91 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 3.98 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.53 earnings per share. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.18% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of recent research reports. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, November 28th. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Piper Sandler reiterated a "neutral" rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Finally, Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $539.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.